<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442351</url>
  </required_header>
  <id_info>
    <org_study_id>P04654</org_study_id>
    <secondary_id>IND Number: 46216; SCH 032088</secondary_id>
    <nct_id>NCT00442351</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)</brief_title>
  <official_title>A Comparative Study of The Efficacy and Tolerability of Maintenance Treatment of Patients With Mild/Moderate Persistent Asthma With Asmanex Twisthaler 220 mcg QD PM Versus &quot;Asmanex&quot; Placebo QD PM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study
      evaluating Asmanex Twisthaler 220 mcg once daily (QD) in the evening (PM) compared with
      &quot;Asmanex&quot; Placebo QD PM for 12 weeks. Efficacy will be measured for the changes in forced
      expiratory volume in 1 second (FEV1) from baseline to the end of treatment period (Week 12 or
      end of the study).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Enrollment
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Final/Terminal Visit in Forced Expiratory Value in 1 Second (FEV1) in Morning Office Measurements.</measure>
    <time_frame>Twelve (12) weeks</time_frame>
    <description>The baseline value for this outcome measure was evaluated at the baseline visit prior to randomization. The change from Baseline to final/terminal visit in FEV1 was to be analyzed using an Analysis of Covariance (ANCOVA) model.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Asmanex Twisthaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo inhaler</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asmanex twisthaler</intervention_name>
    <description>Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks</description>
    <arm_group_label>Asmanex Twisthaler</arm_group_label>
    <other_name>Mometasone furoate inhalation powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for Asmanex twisthaler</intervention_name>
    <description>Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks</description>
    <arm_group_label>Placebo inhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign informed consent

          -  Be 18-75 years of age, of either sex and any race

          -  Have asthma for &gt;= 12 months

          -  Have mild or moderate persistent asthma

          -  Prior to completing Screening Visit procedures, must be using: low or moderate doses
             of an inhaled corticosteroid (IC), with a short-acting beta-2 agonist (SABA) as needed
             (prn) or a SABA prn as monotherapy. Those using a combination ICs plus long-acting
             beta-2 agonist (LABA) medication, such as Advair 100/50 twice daily (BID), must be
             changed to fluticasone propionate 100 mcg BID for at least 5 days prior to the start
             of Run-In-Period. Those using LABA as monotherapy must be switched to SABA prn for at
             least 5 days prior to the start of Run-In Period

          -  Be off treatment with leukotriene receptor antagonist (LTRA) for at least 14 days
             prior to Screening

          -  Have an FEV1 &gt;=65% but &lt;=85% of predicted normal value at Screening and at Baseline
             when SABAs have been withheld for at least 6 hours

          -  Demonstrate an increase of absolute FEV1 of &gt;= 12% with an absolute volume increase of
             at least 200mL during Screening. Written documentation of FEV1 reversibility of &gt;= 12%
             within 2 years prior to Screening was acceptable in lieu of testing. FEV1
             reversibility testing should be done after withholding inhaled SABA for at least 6
             hours

          -  Have a frequency of asthma score of at least 2 (at least 2 symptoms) and/or frequency
             of bronchodilator use score of at least 2 at Screening

          -  Have a Total Asthma Severity Score (TASS) of at least 4 on 8 or more of the AM and PM
             recordings from the last 7 days during the Run-in period prior to Baseline and the AM
             of the Baseline Visit

          -  At Screening Visit, have sleep disturbance and scores of &gt;=2 on the interference with
             sleep rating scale (recall over the past 7 nights), and at least 30 on the Medical
             Outcomes Study Sleep scale (MOS-SS) Sleep Disturbance Sleep Scale (recall over the
             past 7 days)

          -  At the Baseline Visit, must have sleep disturbance and scores of &gt;= 2 on interference
             with sleep rating scale (recorded in a diary during the past 7 nights), and at least
             30 on the MOS-SS Sleep Problems Index II 9 items(SLP 9)

        Exclusion Criteria

          -  Women who are pregnant or intend to become pregnant during the study

          -  Women who are nursing or intend to nurse during the study or within 30 days after
             completion

          -  Have participated in any clinical trial within the last 30 days or in one involving
             antibodies for asthma or rhinitis within 3 months prior to Screening

          -  Have had an unscheduled medical visit (due to exacerbation of asthma) within 1 month
             prior to Screening

          -  Have been treated in the emergency room or admitted to the hospital due to
             exacerbation of asthma on two or more occasions within the 12 months prior to
             Screening

          -  Have used &gt;12 puffs of rescue SABAs or 2 treatments with a nebulized beta-2-agonist
             per day on 2 consecutive days within 4 weeks prior to Screening

          -  Required more than 2 courses of oral/systemic corticosteroids for asthma within 12
             months prior to Screening

          -  Have a history of sleep disorders, including narcolepsy, or use of medications that
             affect alertness or sleep

          -  Have sleep apnea, obstructive sleep apnea-hypopnea, or are being treated with the
             ventilation devices Continuous Positive Airway Pressure (CPAP) or (Bi-level Positive
             Airway Pressure (Bi-PAP), or are receiving oxygen by inhalation

          -  Are smokers or ex-smokers who have smoked within 6 months prior to

        Screening or have a cumulative smoking history of 10 pack-years or greater

          -  Are allergic to corticosteroids, SABAs, or LABAs

          -  Required ventilator support for respiratory failure secondary to asthma in the last 10
             years

          -  Have a Body-Mass-Index greater than 35
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>March 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2010</results_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Asmanex Twisthaler</title>
          <description>Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Inhaler</title>
          <description>Placebo for Asmanex Twisthaler 220 mcg, provided once daily in the evening for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17">Due to poor enrollment and a high screening failure rate, this study was terminated early.</participants>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Asmanex Twisthaler</title>
          <description>Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo Inhaler</title>
          <description>Placebo for Asmanex Twisthaler 220 mcg, provided once daily in the evening for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="11.9"/>
                    <measurement group_id="B2" value="42.6" spread="17.0"/>
                    <measurement group_id="B3" value="42.1" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Final/Terminal Visit in Forced Expiratory Value in 1 Second (FEV1) in Morning Office Measurements.</title>
        <description>The baseline value for this outcome measure was evaluated at the baseline visit prior to randomization. The change from Baseline to final/terminal visit in FEV1 was to be analyzed using an Analysis of Covariance (ANCOVA) model.</description>
        <time_frame>Twelve (12) weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Asmanex Twisthaler</title>
            <description>Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Inhaler</title>
            <description>Placebo for Asmanex Twisthaler 220 mcg, provided once daily in the evening for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Final/Terminal Visit in Forced Expiratory Value in 1 Second (FEV1) in Morning Office Measurements.</title>
          <description>The baseline value for this outcome measure was evaluated at the baseline visit prior to randomization. The change from Baseline to final/terminal visit in FEV1 was to be analyzed using an Analysis of Covariance (ANCOVA) model.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Asmanex Twisthaler</title>
          <description>Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo Inhaler</title>
          <description>Placebo for Asmanex Twisthaler 220 mcg, provided once daily in the evening for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Scar excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI is not allowed to release any interim results of the Study without prior consent of the sponsor, and must provide 45 days written notice to the sponsor prior to public release to permit the sponsor's review. The PI can use the study results for his/her own teaching, research, and publication purposes only, not for commercial purposes, except as authorized by the sponsor. No publication shall contain any trade secret or proprietary/confidential information of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early due to a high screening failure rate and poor enrollment that resulted from stringent inclusion and exclusion criteria. Efficacy data were not evaluated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

